Guided Therapeutics (GTHP) Free Cash Flow (2011 - 2025)
Guided Therapeutics (GTHP) reported Free Cash Flow of -$291000.0 for Q4 2025, up 12.35% on a YoY basis from -$259013.4 in Q4 2024, and down 5.05% sequentially from -$277000.0 in Q3 2025.
Guided Therapeutics (GTHP) Free Cash Flow (2011 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 15 years of Free Cash Flow data on file, last reported at -$291000.0 in Q4 2025.
- For the quarter ending Q4 2025, Free Cash Flow rose 12.35% year-over-year to -$291000.0; the trailing twelve-month figure through Dec 2025 stood at -$1.1 million (up 4.56% YoY), and the FY2025 full-year result was -$1.1 million, up 4.38% from the prior year.
- Free Cash Flow fell to -$291000.0 in Q4 2025, from -$277000.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $128000.0 in Q4 2021 to a low of -$717000.0 in Q3 2021.
- A 5-year average of -$352450.0 and a median of -$334000.0 in 2023 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow soared 138.67% in 2021 and tumbled 367.19% in 2022, its largest moves.
- Tracing GTHP's Free Cash Flow over 5 years: stood at $128000.0 in 2021, then plunged by 367.19% to -$342000.0 in 2022, then increased by 1.75% to -$336000.0 in 2023, then advanced by 1.19% to -$332000.0 in 2024, then climbed by 12.35% to -$291000.0 in 2025.
- Business Quant data shows GTHP's Free Cash Flow at -$291000.0 in Q4 2025, -$277000.0 in Q3 2025, and -$169000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 916.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 415.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 2.09 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 171.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -21.10 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 449.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 305.56 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 112.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | -291,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -291,000.00 |
| Dec 31, 2025 | -291,000.00 |
| Sep 30, 2025 | -277,000.00 |
| Sep 30, 2025 | -277,000.00 |
| Jun 30, 2025 | -169,000.00 |
| Jun 30, 2025 | -169,000.00 |
| Mar 31, 2025 | -331,000.00 |
| Mar 31, 2025 | -331,000.00 |
| Dec 31, 2024 | -332,000.00 |
| Dec 31, 2024 | -332,000.00 |
| Sep 30, 2024 | -473,000.00 |
| Sep 30, 2024 | -473,000.00 |
| Jun 30, 2024 | -214,000.00 |
| Jun 30, 2024 | -214,000.00 |
| Mar 31, 2024 | -100,000.00 |
| Mar 31, 2024 | -100,000.00 |
| Dec 31, 2023 | -336,000.00 |
| Dec 31, 2023 | -336,000.00 |
| Sep 30, 2023 | -473,000.00 |
| Sep 30, 2023 | -473,000.00 |